Treatment persistence and compliance with medications for chronic obstructive pulmonary disease

BACKGROUND AND OBJECTIVE: Inhaled beta-agonist, anticholinergic and glucocorticoid medications are used to treat asthma pulmonary disease (COPD). The present and chronic obstructive study assessed the patterns of persistence with the above mentioned inhaled medications. METHODS: Prescription claims data from the Ontario Drug, Benefit program were analyzed to assess persistence (time to discontinuation) and Compliance (Percentage of clays with closes available divided by days to last refill) of patients prescribed inhaled medications. Patients were grouped as naive (no inhaled medication in the previous year) or experienced (previous Or current treatment), and by age (18 to 65 years of age and older than 65 years of age). Medications included ipratropium, ipratropium plus salbutanol, formoterol, formoterol plus budesonide, salmeterol, salmeterol plus fluticasone, and tiotropium. RESULTS: The database included 3 1,368 patients (4888 naive and 26,480 experienced) who were Prescribed at least one of these medications. Fifteen Per cent to 63% of patients continued on the index drug for more than six months, which decreased to 7% to 53% at 12 months, and 5% to 47% at 18 months. At 12 months, Patients taking tiotropium had significantly longer persistence compared with other therapies (53% versus 7% to 30%; all P<0.0001), and fewer switches to alternative medications. Most naive patients had significantly shorter treatment Persistence than experienced patients for all drugs (all P<0.0001), including tiotropium (27% versus 55%, P<0.0001). Compliance rates were similar for all drugs (ie, 76% to 94%) but were highest for tiotropium. CONCLUSIONS: These data demonstrated that persistence with inhaled treatment was tow overall, but patients treated with tiotropium remained on therapy significantly longer than when treated with other medications, and Patients naive to inhaled treatment had shorter treatment persistence than experienced patients.